OSCR

PARP4 drives tumor progression by promoting glioma cell proliferation and invasion as a potential therapeutic target.

Overview

Authors: Bingqi Lu1,2, Zhou Jing1,2, Fangyuan Wang1,2, Minghe Li1,2, Ao Huo1,2, Chenglin Zhao3,2, Zhongyu Zhao1,2, Qingyi Wang1,2, Hao Li1,2, Wulong Liang1,2, Weihua Hu1,2, Xudong Fu1,3
  1. Department of Neurosurgery, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, China
  2. Henan Provincial Key Laboratory of Cranial Nerve Diseases, Zhengzhou University, Zhengzhou, China
  3. Department of Neurosurgery, Henan Provincial People’s Hospital, Zhengzhou University, Zhengzhou, China
Journal: Discover oncology, volume 17, issue 1, article 813
Dates: received 4 December 2025; accepted 6 April 2026; published online 18 April 2026
Type: Research article · Language: English
License: CC BY-NC-ND
Identifiers: DOI 10.1007/s12672-026-04980-8 · PMID 41999525 · PMCID PMC13219579 · OpenAlex W7154853159
Open access: gold, a free copy (OpenAlex)
Categories: human (organism), other condition (population), clinical / translational (subfield)
Methods: Statistics, Connectivity
Keywords: Glioma, PARP4, Prognosis, Migration and invasion, Therapeutic target
Topic: PARP inhibition in cancer therapy (Oncology, Medicine), according to OpenAlex
Funding: National Natural Science Foundation of China (82303029); Science and Technology Department of Henan Province (232102311134); Zhengzhou Science and Technology Innovation Project for Healthcare (2024YLZDJH027)
Citations: not cited yet (Europe PMC); 39 references in the paper

Abstract

The abstract is not reproduced here: the paper's license (CC BY-NC-ND) does not allow it. Read it in the paper, at the publisher or on Europe PMC.

Code

The paper links to its data and to no code of its authors: see the Data section.

Tracing map

A tracing map links a paper to the code its authors published: this paper has none, so it has no map.

Data

Datasets cited

Other data links

Data availability statement

The paper has a data availability statement. Its license (CC BY-NC-ND) does not allow reproducing it here; in short, from what the harvester recognized in it:

  • it points to a dataset: NCBI
  • it says that the data are available on request

Read it in the paper: doi.org/10.1007/s12672-026-04980-8.

Versions

The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.

Version 1, 29 September 2026: the first record

Recorded: type, language, journal, volume, issue, pages, dates, 12 authors, 5 keywords, 3 funders, 38 references.

Cite

This paper

Lu, B., Jing, Z., Wang, F., Li, M., Huo, A., Zhao, C., Zhao, Z., Wang, Q., Li, H., Liang, W., Hu, W., & Fu, X. (2026). PARP4 drives tumor progression by promoting glioma cell proliferation and invasion as a potential therapeutic target. Discover oncology, 17(1), 813. https://doi.org/10.1007/s12672-026-04980-8

BibTeX

@article{lu2026parp4,
author = {Lu, Bingqi and Jing, Zhou and Wang, Fangyuan and Li, Minghe and Huo, Ao and Zhao, Chenglin and Zhao, Zhongyu and Wang, Qingyi and Li, Hao and Liang, Wulong and Hu, Weihua and Fu, Xudong},
title = {{PARP4 drives tumor progression by promoting glioma cell proliferation and invasion as a potential therapeutic target}},
journal = {Discover oncology},
year = {2026},
month = apr,
volume = {17},
number = {1},
pages = {813},
publisher = {Springer},
issn = {2730-6011},
doi = {10.1007/s12672-026-04980-8},
url = {https://doi.org/10.1007/s12672-026-04980-8},
pmid = {41999525},
pmcid = {PMC13219579}
}

RIS

TY - JOUR
AU - Lu, Bingqi
AU - Jing, Zhou
AU - Wang, Fangyuan
AU - Li, Minghe
AU - Huo, Ao
AU - Zhao, Chenglin
AU - Zhao, Zhongyu
AU - Wang, Qingyi
AU - Li, Hao
AU - Liang, Wulong
AU - Hu, Weihua
AU - Fu, Xudong
TI - PARP4 drives tumor progression by promoting glioma cell proliferation and invasion as a potential therapeutic target
T2 - Discover oncology
J2 - Discov Oncol
PY - 2026
DA - 2026/04/18
VL - 17
IS - 1
SP - 813
SN - 2730-6011
PB - Springer
DO - 10.1007/s12672-026-04980-8
UR - https://doi.org/10.1007/s12672-026-04980-8
LA - en
ER -

CSL-JSON

{
"id": "10.1007/s12672-026-04980-8",
"type": "article-journal",
"title": "PARP4 drives tumor progression by promoting glioma cell proliferation and invasion as a potential therapeutic target",
"container-title": "Discover oncology",
"author": [
{
"family": "Lu",
"given": "Bingqi"
},
{
"family": "Jing",
"given": "Zhou"
},
{
"family": "Wang",
"given": "Fangyuan"
},
{
"family": "Li",
"given": "Minghe"
},
{
"family": "Huo",
"given": "Ao"
},
{
"family": "Zhao",
"given": "Chenglin"
},
{
"family": "Zhao",
"given": "Zhongyu"
},
{
"family": "Wang",
"given": "Qingyi"
},
{
"family": "Li",
"given": "Hao"
},
{
"family": "Liang",
"given": "Wulong"
},
{
"family": "Hu",
"given": "Weihua"
},
{
"family": "Fu",
"given": "Xudong"
}
],
"container-title-short": "Discov Oncol",
"volume": "17",
"issue": "1",
"page": "813",
"DOI": "10.1007/s12672-026-04980-8",
"PMID": "41999525",
"PMCID": "PMC13219579",
"ISSN": "2730-6011",
"publisher": "Springer",
"URL": "https://doi.org/10.1007/s12672-026-04980-8",
"language": "en",
"issued": {
"date-parts": [
[
2026,
4,
18
]
]
}
}

Similar papers

The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.

[1] doi:10.3389/fimmu.2022.917014
DDOST Correlated with Malignancies and Immune Microenvironment in Gliomas.
Journal: Frontiers in immunology
In common: NCBI GEO GSE4290, clinical / translational, other condition, 1 reference
[2] doi:10.1186/s40644-026-01052-6 [code]
Microstructure mapping with time-dependent diffusion MRI differentiates primary central nervous system lymphoma from glioblastoma.
Journal: Cancer imaging : the official publication of the International Cancer Imaging Society
In common: clinical / translational, other condition, 3 references
[3] doi:10.1038/s41598-024-61515-3
Identification of candidate biomarkers for GBM based on WGCNA.
Journal: Scientific reports
In common: NCBI GEO GSE4290, clinical / translational, other condition
[4] doi:10.1186/s12885-023-10896-1
Integrated profiling identifies CACNG3 as a prognostic biomarker for patients with glioma.
Journal: BMC cancer
In common: NCBI GEO GSE4290, clinical / translational, other condition
[5] doi:10.1016/j.tranon.2023.101739
Identification of LOX as a candidate prognostic biomarker in Glioblastoma multiforme.
Journal: Translational oncology
In common: NCBI GEO GSE4290, clinical / translational, other condition
[6] doi:10.2147/cmar.s367020
Identification of Novel tRNA-Leu-CAA-Derived tsRNAs for the Diagnosis and Prognosis of Diffuse Gliomas.
Journal: Cancer management and research
In common: NCBI GEO GSE4290, clinical / translational, other condition
[7] doi:10.3389/fgene.2022.931938
Identification of a Five-mRNA Signature as a Novel Potential Prognostic Biomarker for Glioblastoma by Integrative Analysis.
Journal: Frontiers in genetics
In common: NCBI GEO GSE4290, clinical / translational, other condition
[8] doi:10.1155/2022/8972730
Identification of an Inflammatory Response-Related Gene Signature to Predict Survival and Immune Status in Glioma Patients.
Journal: Journal of immunology research
In common: NCBI GEO GSE4290, clinical / translational, other condition
[9] doi:10.3389/fphar.2026.1797067
Network-driven prioritization and functional phenotyping nominate TTC23 as a biomarker-informed target in chlorpromazine repurposing for glioblastoma.
Journal: Frontiers in pharmacology
In common: NCBI GEO GSE4290, clinical / translational, other condition
[10] doi:10.1007/s12672-025-04375-1
VAMP5 promotes glioma progression through bioinformatics analysis clinical correlation and functional validation.
Journal: Discover oncology
In common: NCBI GEO GSE4290, clinical / translational, other condition

Contribute

The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.

Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.

Request its removal

To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).

Discussion, reproductions, activity

Discussion: code errors and mismatches between the code and the paper about this paper and its code, from readers and its authors, beside the paper and its tracing map.

Reproductions: reports from readers who ran the authors' code and did not get the paper's result, what they ran, with which environment, commit and data.

Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.